

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES
Investment Company Act file number 811-22525
(Exact name of registrant as specified in charter)
615 East Michigan Street
Milwaukee,
WI 53202
(Address of principal executive offices) (Zip code)
Brian Wiedmeyer, President
Managed Portfolio Series
c/o U.S. Bank Global Fund Services
777 East Wisconsin Ave., 6th Floor
Milwaukee,
WI 53202
(Name and address of agent for service)
(414) 516-1712
Registrant’s telephone number, including area code
Date of fiscal year end: 07/31/2025
Date of reporting period:
Item 1. Reports to Stockholders.
(a) |
![]() |
|
![]() |
|
||
Semi-Annual Shareholder Report |
|
Class Name
|
Costs of a $10,000 investment
|
Costs paid as a percentage of a $10,000 investment
|
Advisor Class
|
$
|
|
Net Assets
|
$
|
Number of Holdings
|
|
Portfolio Turnover
|
|
Top 10 Issuers
|
(%)
|
UnitedHealth Group
|
|
Cencora
|
|
Ross Stores
|
|
Thermo Fisher Scientific
|
|
Lowe’s Companies
|
|
Walt Disney
|
|
Sysco
|
|
Marsh & McLennan Companies
|
|
Philip Morris International
|
|
US Bancorp
|
|
Coho Relative Value Equity Fund | PAGE 1 | TSR-SAR-56166Y636 |
![]() |
|
![]() |
|
||
Semi-Annual Shareholder Report |
|
Class Name
|
Costs of a $10,000 investment
|
Costs paid as a percentage of a $10,000 investment
|
Advisor Class
|
$
|
|
Net Assets
|
$
|
Number of Holdings
|
|
Portfolio Turnover
|
|
Top 10 Issuers
|
(%)
|
UnitedHealth Group
|
|
Ross Stores
|
|
Lowe’s Companies
|
|
Cencora
|
|
Thermo Fisher Scientific
|
|
Abbott Laboratories
|
|
Sysco
|
|
US Bancorp
|
|
W.W. Grainger
|
|
Walt Disney
|
|
Coho Relative Value ESG Fund | PAGE 1 | TSR-SAR-56166Y222 |
(b) | Not applicable. |
Item 2. Code of Ethics.
Not applicable for semi-annual reports.
Item 3. Audit Committee Financial Expert.
Not applicable for semi-annual reports.
Item 4. Principal Accountant Fees and Services.
Not applicable
Item 5. Audit Committee of Listed Registrants.
Not applicable
Item 6. Investments.
(a) | Schedule of Investments is included within the financial statements filed under Item 7 of this Form. |
(b) | Not applicable |
Item 7. Financial Statements and Financial Highlights for Open-End Investment Companies.
(a) |
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Value |
COMMON
STOCKS - 96.7% |
|
|
|
|
||
Communication
Services - 4.1% |
|
|
|
|
||
Walt
Disney |
|
|
72,326 |
|
|
$8,177,178
|
Consumer
Discretionary - 15.8% |
|
|
|
|
||
AutoZone(a) |
|
|
1,960 |
|
|
6,566,411
|
Lowe’s
Companies |
|
|
33,819 |
|
|
8,794,293
|
Ross
Stores |
|
|
63,230 |
|
|
9,519,909
|
Service
Corp. International |
|
|
83,568 |
|
|
6,528,332
|
|
|
|
|
31,408,945
| ||
Consumer
Staples - 18.1% |
|
|
|
|
||
Coca-Cola |
|
|
68,596 |
|
|
4,354,474
|
Constellation
Brands - Class A |
|
|
23,653 |
|
|
4,276,462
|
Keurig
Dr. Pepper |
|
|
205,051 |
|
|
6,582,137
|
Mondelez
International - Class A |
|
|
102,120 |
|
|
5,921,939
|
Philip
Morris International |
|
|
53,442 |
|
|
6,958,149
|
Sysco |
|
|
109,172 |
|
|
7,960,822
|
|
|
|
|
36,053,983
| ||
Energy
- 2.9% |
|
|
|
|
||
Chevron |
|
|
38,752 |
|
|
5,781,411
|
Financials
- 15.3% |
|
|
|
|
||
Global
Payments |
|
|
47,666 |
|
|
5,379,108
|
Marsh
& McLennan Companies |
|
|
32,921 |
|
|
7,139,907
|
State
Street |
|
|
46,384 |
|
|
4,713,542
|
US
Bancorp |
|
|
141,980 |
|
|
6,783,804
|
W
R Berkley |
|
|
108,935 |
|
|
6,408,646
|
|
|
|
|
30,425,007
| ||
Health
Care - 29.4%(b) |
|
|
|
|
||
Abbott
Laboratories |
|
|
47,036 |
|
|
6,017,315
|
Amgen |
|
|
22,258 |
|
|
6,352,878
|
Baxter
International |
|
|
105,721 |
|
|
3,442,276
|
Cencora |
|
|
38,210 |
|
|
9,713,364
|
Johnson
& Johnson |
|
|
42,974 |
|
|
6,538,494
|
Medtronic
PLC |
|
|
74,195 |
|
|
6,738,390
|
Thermo
Fisher Scientific |
|
|
15,465 |
|
|
9,244,204
|
UnitedHealth
Group |
|
|
19,353 |
|
|
10,498,809
|
|
|
|
|
58,545,730
| ||
Industrials
- 5.4% |
|
|
|
|
||
United
Parcel Service - Class B |
|
|
38,657 |
|
|
4,415,789
|
W.W.
Grainger |
|
|
5,913 |
|
|
6,283,568
|
|
|
|
|
10,699,357
| ||
Information
Technology - 2.8% |
|
|
|
|
||
Microchip
Technology |
|
|
104,144 |
|
|
5,655,019
|
Materials
- 2.9% |
|
|
|
|
||
Air
Products and Chemicals |
|
|
17,461 |
|
|
5,853,975
|
TOTAL
COMMON STOCKS
(Cost
$173,876,395) |
|
|
|
|
192,600,605
| |
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Value |
TOTAL
INVESTMENTS - 96.7%
(Cost
$173,876,395) |
|
|
|
|
$192,600,605
| |
Money
Market Deposit Account - 3.1%(c) |
|
|
|
|
6,231,071
| |
Other
Assets in Excess of Liabilities - 0.2% |
|
|
|
|
414,596
| |
TOTAL
NET ASSETS - 100.0% |
|
|
|
|
$199,246,272 | |
|
|
|
|
|
|
|
(a) |
Non-income producing
security. |
(b) |
To the extent that
the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments
that significantly affect those industries or sectors. |
(c) |
The U.S. Bank Money
Market Deposit Account (the “MMDA”) is a short-term vehicle in which the Fund holds cash balances. The MMDA will bear interest
at a variable rate that is determined based on market conditions and is subject to change daily. The rate as of January 31, 2025
was 2.47%. |
|
2 |
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
|
Value |
COMMON
STOCKS - 95.8% |
|
|
|
|
||
Communication
Services - 4.0% |
|
|
|
|
||
Walt
Disney |
|
|
13,167 |
|
|
$1,488,661
|
Consumer
Discretionary - 17.4% |
|
|
|
|
||
AutoZone(a) |
|
|
422 |
|
|
1,413,788
|
Lowe’s
Companies |
|
|
6,866 |
|
|
1,785,435
|
Ross
Stores |
|
|
12,428 |
|
|
1,871,160
|
Service
Corp. International |
|
|
18,167 |
|
|
1,419,206
|
|
|
|
|
6,489,589
| ||
Consumer
Staples - 19.2% |
|
|
|
|
||
Coca-Cola |
|
|
13,917 |
|
|
883,451
|
Colgate-Palmolive |
|
|
12,232 |
|
|
1,060,514
|
Kenvue |
|
|
48,279 |
|
|
1,027,860
|
Keurig
Dr. Pepper |
|
|
40,550 |
|
|
1,301,655
|
Mondelez
International - Class A |
|
|
22,536 |
|
|
1,306,863
|
Sysco |
|
|
21,818 |
|
|
1,590,969
|
|
|
|
|
7,171,312
| ||
Financials
- 15.0% |
|
|
|
|
||
Global
Payments |
|
|
10,675 |
|
|
1,204,674
|
Marsh
& McLennan Companies |
|
|
6,634 |
|
|
1,438,782
|
State
Street |
|
|
13,946 |
|
|
1,417,192
|
US
Bancorp |
|
|
32,704 |
|
|
1,562,597
|
|
|
|
|
5,623,245
| ||
Health
Care - 32.8%(b) |
|
|
|
|
||
Abbott
Laboratories |
|
|
13,080 |
|
|
1,673,324
|
Amgen |
|
|
4,407 |
|
|
1,257,846
|
Baxter
International |
|
|
33,847 |
|
|
1,102,058
|
Cencora |
|
|
6,935 |
|
|
1,762,946
|
Johnson
& Johnson |
|
|
8,965 |
|
|
1,364,025
|
Medtronic
PLC |
|
|
15,758 |
|
|
1,431,142
|
Thermo
Fisher Scientific |
|
|
2,883 |
|
|
1,723,313
|
UnitedHealth
Group |
|
|
3,595 |
|
|
1,950,252
|
|
|
|
|
12,264,906
| ||
Industrials
- 4.0% |
|
|
|
|
||
W.W.
Grainger |
|
|
1,417 |
|
|
1,505,803
|
Information
Technology - 3.4% |
|
|
|
|
||
Microchip
Technology |
|
|
23,145 |
|
|
1,256,774
|
TOTAL
COMMON STOCKS
(Cost
$33,112,840) |
|
|
|
|
35,800,290
| |
TOTAL
INVESTMENTS - 95.8%
(Cost
$33,112,840) |
|
|
|
|
$35,800,290
| |
Money
Market Deposit Account - 4.2%(c) |
|
|
|
|
1,586,949
| |
Liabilities
in Excess of Other Assets - (0.0)%(d) |
|
|
|
|
(25)
| |
TOTAL
NET ASSETS - 100.0% |
|
|
|
|
$37,387,214 | |
|
|
|
|
|
|
|
|
3 |
|
(a) |
Non-income producing
security. |
(b) |
To the extent that
the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments
that significantly affect those industries or sectors. |
(c) |
The U.S. Bank Money
Market Deposit Account (the “MMDA”) is a short-term vehicle in which the Fund holds cash balances. The MMDA will bear interest
at a variable rate that is determined based on market conditions and is subject to change daily. The rate as of January 31, 2025
was 2.47%. |
(d) |
Represents less than
0.05% of net assets. |
|
4 |
|
|
|
|
|
|
|
|
|
|
|
Coho Relative
Value Equity
Fund |
|
|
Coho Relative
Value ESG
Fund |
ASSETS: |
|
|
|
|
||
Investments,
at value |
|
|
|
|
||
(Cost:
$173,876,395 & $33,112,840 respectively) |
|
|
$192,600,605 |
|
|
$35,800,290
|
Cash
Equivalent |
|
|
6,231,071 |
|
|
1,586,949
|
Dividends
and interest receivable |
|
|
144,338 |
|
|
30,800
|
Receivable
for capital shares sold |
|
|
122,121 |
|
|
—
|
Receivable
for investment securities sold |
|
|
1,799,027 |
|
|
—
|
Prepaid
expenses |
|
|
9,957 |
|
|
14,344
|
Total
assets |
|
|
200,907,119 |
|
|
37,432,383
|
LIABILITIES: |
|
|
|
|
||
Payable
to investment adviser |
|
|
102,064 |
|
|
9,304
|
Payable
for capital shares redeemed |
|
|
1,456,118 |
|
|
—
|
Payable
for fund administration & accounting fees |
|
|
35,465 |
|
|
6,843
|
Payable
for audit fees |
|
|
10,221 |
|
|
11,110
|
Payable
for custody fees |
|
|
26,637 |
|
|
3,401
|
Payable
for transfer agent fees & expenses |
|
|
7,767 |
|
|
3,372
|
Payable
for trustee fees |
|
|
5,249 |
|
|
4,810
|
Payable
for compliance fees |
|
|
2,087 |
|
|
2,087
|
Accrued
expenses |
|
|
15,239 |
|
|
4,242
|
Total
liabilities |
|
|
1,660,847 |
|
|
45,169
|
NET
ASSETS |
|
|
$199,246,272 |
|
|
$37,387,214
|
NET
ASSETS CONSIST OF: |
|
|
|
|
||
Paid-in
capital |
|
|
$165,855,163 |
|
|
$36,445,609
|
Total
distributable earnings |
|
|
33,391,109 |
|
|
941,605
|
Net
assets |
|
|
$
199,246,272 |
|
|
$37,387,214
|
Net
Assets |
|
|
$199,246,272 |
|
|
$37,387,214
|
Shares
issued and outstanding(1) |
|
|
15,471,017 |
|
|
3,166,396
|
Net
asset value, redemption price and offering price per share |
|
|
$12.88 |
|
|
$11.81 |
|
|
|
|
|
|
|
(1) |
Unlimited shares authorized
without par value. |
|
5 |
|
|
|
|
|
|
|
|
|
|
|
Coho Relative
Value Equity
Fund |
|
|
Coho Relative
Value ESG
Fund |
INVESTMENT
INCOME: |
|
|
|
|
||
Dividend
income |
|
|
$3,332,116 |
|
|
$391,345
|
Interest
income |
|
|
136,759 |
|
|
25,597
|
Total
investment income |
|
|
3,468,875 |
|
|
416,942
|
EXPENSES: |
|
|
|
|
||
Investment
adviser fees (See Note 4) |
|
|
1,118,201 |
|
|
144,992
|
Fund
administration & accounting fees (See Note 4) |
|
|
127,238 |
|
|
24,342
|
Custody
fees (See Note 4) |
|
|
27,928 |
|
|
4,784
|
Transfer
agent fees & expenses (See Note 4) |
|
|
23,217 |
|
|
10,641
|
Federal
& state registration fees |
|
|
17,026 |
|
|
11,178
|
Trustee
fees |
|
|
11,940 |
|
|
11,448
|
Audit
fees |
|
|
10,222 |
|
|
9,610
|
Legal
fees |
|
|
9,482 |
|
|
10,324
|
Postage
& printing fees |
|
|
7,524 |
|
|
1,592
|
Compliance
fees (See Note 4) |
|
|
6,256 |
|
|
6,256
|
Other
expenses |
|
|
3,722 |
|
|
2,188
|
Insurance
fees |
|
|
2,842 |
|
|
1,288
|
Total
expenses before interest expense, waiver |
|
|
1,365,598 |
|
|
238,643
|
Interest
expense (See Note 10) |
|
|
8,008 |
|
|
—
|
Total
expenses before waiver |
|
|
1,373,606 |
|
|
238,643
|
Less:
waiver from investment adviser (See Note 4) |
|
|
(103,629) |
|
|
(75,009)
|
Net
expenses |
|
|
1,269,977 |
|
|
163,634
|
NET
INVESTMENT INCOME |
|
|
2,198,898 |
|
|
253,308
|
REALIZED
AND UNREALIZED GAIN (LOSS) ON INVESTMENTS |
|
|
|
|
||
Net
realized gain on investments |
|
|
30,152,247 |
|
|
55,323
|
Net
change in unrealized appreciation/depreciation on investments |
|
|
(33,244,022) |
|
|
(257,379)
|
Net
realized and unrealized loss on investments |
|
|
(3,091,775) |
|
|
(202,056)
|
NET
INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS |
|
|
$(892,877) |
|
|
$51,252 |
|
|
|
|
|
|
|
|
6 |
|
|
|
|
|
|
|
|
|
|
|
Period Ended
January 31,
2025
(Unaudited) |
|
|
Year Ended
July 31,
2024 |
OPERATIONS: |
|
|
|
|
||
Net
investment income |
|
|
$2,198,898 |
|
|
$9,280,862
|
Net
realized gain on investments |
|
|
30,152,247 |
|
|
53,141,915
|
Net
change in unrealized appreciation/depreciation on investments |
|
|
(33,244,022) |
|
|
(57,425,262)
|
Net
increase (decrease) in net assets resulting from operations |
|
|
(892,877) |
|
|
4,997,515
|
CAPITAL
SHARE TRANSACTIONS: |
|
|
|
|
||
Proceeds
from shares sold |
|
|
10,903,609 |
|
|
67,728,359
|
Proceeds
from reinvestment of distributions |
|
|
28,198,887 |
|
|
48,733,921
|
Payments
for shares redeemed |
|
|
(222,121,054) |
|
|
(477,504,175)
|
Net
decrease in net assets resulting from capital share transactions |
|
|
(183,018,558) |
|
|
(361,041,895)
|
DISTRIBUTIONS
TO SHAREHOLDERS |
|
|
(34,503,030) |
|
|
(67,479,859)
|
TOTAL
DECREASE IN NET ASSETS |
|
|
(218,414,465) |
|
|
(423,524,239)
|
NET
ASSETS: |
|
|
|
|
||
Beginning
of period |
|
|
417,660,737 |
|
|
841,184,976
|
End
of period |
|
|
$199,246,272 |
|
|
$417,660,737 |
|
|
|
|
|
|
|
|
7 |
|
|
|
|
|
|
|
|
|
|
|
Period Ended
January 31,
2025
(Unaudited) |
|
|
Year Ended
July 31,
2024 |
OPERATIONS: |
|
|
|
|
||
Net
investment income |
|
|
$253,308 |
|
|
$715,679
|
Net
realized gain (loss) on investments |
|
|
55,323 |
|
|
(1,890,022)
|
Net
change in unrealized appreciation/depreciation on investments |
|
|
(257,379) |
|
|
2,924,483
|
Net
increase in net assets resulting from operations |
|
|
51,252 |
|
|
1,750,140
|
CAPITAL
SHARE TRANSACTIONS: |
|
|
|
|
||
Proceeds
from shares sold |
|
|
860,287 |
|
|
3,861,094
|
Proceeds
from reinvestment of distributions |
|
|
715,617 |
|
|
1,027,077
|
Payments
for shares redeemed |
|
|
(11,065,314) |
|
|
(13,937,475)
|
Net
decrease in net assets resulting from capital share transactions |
|
|
(9,489,410) |
|
|
(9,049,304)
|
DISTRIBUTIONS
TO SHAREHOLDERS: |
|
|
(715,639) |
|
|
(1,027,100)
|
TOTAL
DECREASE IN NET ASSETS |
|
|
(10,153,797) |
|
|
(8,326,264)
|
NET
ASSETS: |
|
|
|
|
||
Beginning
of period |
|
|
47,541,011 |
|
|
55,867,275
|
End
of period |
|
|
$37,387,214 |
|
|
$47,541,011 |
|
|
|
|
|
|
|
|
8 |
|
|
|
|
|
|
|
| ||||||||||||
|
|
|
Six Months
Ended
January 31,
2025
(Unaudited) |
|
|
Year Ended
July 31, | ||||||||||||
|
2024 |
|
|
2023 |
|
|
2022 |
|
|
2021 |
|
|
2020 | |||||
PER
SHARE DATA(1): |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net
asset value, beginning of period |
|
|
$14.67 |
|
|
$15.83 |
|
|
$16.48 |
|
|
$17.51 |
|
|
$14.42 |
|
|
$14.20 |
INVESTMENT
OPERATIONS: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net
investment income |
|
|
0.17 |
|
|
0.30 |
|
|
0.23(2) |
|
|
0.23(2) |
|
|
0.25(2) |
|
|
0.25(2)
|
Net
realized and unrealized gain (loss) on investments |
|
|
(0.22) |
|
|
0.15(3) |
|
|
0.25 |
|
|
0.12 |
|
|
3.46 |
|
|
0.93
|
Total
from investment operations |
|
|
(0.05) |
|
|
0.45 |
|
|
0.48 |
|
|
0.35 |
|
|
3.71 |
|
|
1.18
|
LESS
DISTRIBUTIONS FROM: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net
investment income |
|
|
(0.31) |
|
|
(0.29) |
|
|
(0.21) |
|
|
(0.24) |
|
|
(0.22) |
|
|
(0.26)
|
Net
realized gains |
|
|
(1.43) |
|
|
(1.32) |
|
|
(0.92) |
|
|
(1.14) |
|
|
(0.40) |
|
|
(0.70)
|
Total
distributions |
|
|
(1.74) |
|
|
(1.61) |
|
|
(1.13) |
|
|
(1.38) |
|
|
(0.62) |
|
|
(0.96)
|
Paid-in
capital from redemption fees |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
—(4) |
|
|
—(4)
|
Net
asset value, end of period |
|
|
$12.88 |
|
|
$14.67 |
|
|
$15.83 |
|
|
$16.48 |
|
|
$17.51 |
|
|
$14.42
|
Total
return(6) |
|
|
−0.47% |
|
|
3.59% |
|
|
3.12% |
|
|
1.96% |
|
|
26.33% |
|
|
8.45%
|
SUPPLEMENTAL
DATA AND RATIOS: | ||||||||||||||||||
Net
assets, end of period (in 000’s) |
|
|
$199,246 |
|
|
$417,661 |
|
|
$841,185 |
|
|
$958,155 |
|
|
$989,261 |
|
|
$741,826
|
Ratio
of expenses to average net assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Before
expense waiver/recoupment(7) |
|
|
0.86% |
|
|
0.81% |
|
|
0.79% |
|
|
0.78% |
|
|
0.78% |
|
|
0.82%
|
After
expense waiver/recoupment(7) |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.81%(5)
|
Ratio
of expenses excluding interest to average net assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Before
expense waiver/reimbursement(7) |
|
|
0.85% |
|
|
0.81% |
|
|
0.79% |
|
|
0.78% |
|
|
0.78% |
|
|
0.82%
|
After
expense waiver/reimbursement(7) |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.81%
|
Ratio
of net investment income to average
net
assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
After
expense waiver/recoupment(7) |
|
|
1.38% |
|
|
1.59% |
|
|
1.50% |
|
|
1.35% |
|
|
1.53% |
|
|
1.76%
|
Portfolio
turnover rate(6) |
|
|
12% |
|
|
19% |
|
|
12% |
|
|
23% |
|
|
26% |
|
|
27% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
On November 22,
2019 the Fund’s Institutional Class shares were merged into the Advisor Class shares. The Advisor Class name was
subsequently discontinued following the merger. |
(2) |
Per share amounts
calculated using the average shares method. |
(3) |
Realized and unrealized
gains per share in this caption are balancing amounts necessary to reconcile the change in net asset value per share for the year, and
may not reconcile with the aggregate gains on the Statement of Operations due to share transactions for the year. |
(4) |
Amount per share is
less than $0.01. |
(5) |
Prior to November 22,
2019, the annual expense limitation was 0.94% of the average daily net assets for the Advisor Class. Thereafter it was 0.79% for the existing
class. |
(6) |
Not Annualized for
periods less than one year. |
(7) |
Annualized for periods
less than one year. |
|
9 |
|
|
|
|
|
|
|
|
|
|
| |||||||||
|
|
|
Six Months
Ended
January 31,
2025
(Unaudited) |
|
|
Year Ended
July 31, |
|
|
Since
Inception(1)
through
July 31,
2020 | |||||||||
|
2024 |
|
|
2023 |
|
|
2022 |
|
|
2021 |
| |||||||
PER
SHARE DATA: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net
asset value, beginning of period |
|
|
$12.08 |
|
|
$11.83 |
|
|
$11.79 |
|
|
$12.43 |
|
|
$10.19 |
|
|
$10.00
|
INVESTMENT
OPERATIONS: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net
investment income |
|
|
0.13 |
|
|
0.20 |
|
|
0.15 |
|
|
0.09 |
|
|
0.08 |
|
|
0.05
|
Net
realized and unrealized gain (loss) on investments |
|
|
(0.17) |
|
|
0.29 |
|
|
0.14 |
|
|
(0.08)(4) |
|
|
2.37 |
|
|
0.15
|
Total
from investment operations |
|
|
(0.04) |
|
|
0.49 |
|
|
0.29 |
|
|
0.01 |
|
|
2.45 |
|
|
0.20
|
LESS
DISTRIBUTIONS FROM: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net
investment income |
|
|
(0.23) |
|
|
(0.17) |
|
|
(0.06) |
|
|
(0.08) |
|
|
(0.05) |
|
|
(0.01)
|
Net
realized gains |
|
|
— |
|
|
(0.07) |
|
|
(0.19) |
|
|
(0.57) |
|
|
(0.16) |
|
|
—
|
Total
distributions |
|
|
(0.23) |
|
|
(0.24) |
|
|
(0.25) |
|
|
(0.65) |
|
|
(0.21) |
|
|
(0.01)
|
Net
asset value, end of period |
|
|
$11.81 |
|
|
$12.08 |
|
|
$11.83 |
|
|
$11.79 |
|
|
$12.43 |
|
|
$10.19
|
Total
return(2) |
|
|
−0.30% |
|
|
4.20% |
|
|
2.52% |
|
|
−0.02% |
|
|
24.26% |
|
|
2.00%
|
SUPPLEMENTAL
DATA AND RATIOS: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Net
assets, end of period (in 000’s) |
|
|
$37,387 |
|
|
$47,541 |
|
|
$55,867 |
|
|
$48,248 |
|
|
$22,203 |
|
|
$3,707
|
Ratio
of expenses to average net assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Before
expense waiver/reimbursement(3) |
|
|
1.15% |
|
|
1.08% |
|
|
1.03% |
|
|
1.14% |
|
|
1.81% |
|
|
9.78%
|
After
expense waiver/reimbursement(3) |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.79% |
|
|
0.79%
|
Ratio
of net investment income to average
net
assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||||
After
expense waiver/reimbursement(3) |
|
|
1.23% |
|
|
1.41% |
|
|
1.44% |
|
|
1.20% |
|
|
1.15% |
|
|
1.48%
|
Portfolio
turnover rate(2) |
|
|
15% |
|
|
17% |
|
|
20% |
|
|
22% |
|
|
25% |
|
|
10% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Inception date for
the Fund was November 27, 2019. |
(2) |
Not annualized for
periods less than one year. |
(3) |
Annualized for periods
less than one year. |
(4) |
Net realized and
unrealized loss per share in this caption is a balancing amount necessary to reconcile changes in net asset value per share for the year,
and may not reconcile with the aggregate gain on the Statement of Operations due to share transactions for the year. |
|
10 |
|
|
11 |
|
Level 1 – |
Unadjusted quoted prices in active markets
for identical assets or liabilities that the Funds has the ability to access. |
Level 2 – |
Observable inputs other than quoted prices
included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices
for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield
curves, default rates and similar data. |
Level 3 – |
Unobservable inputs for the asset or liability,
to the extent relevant observable inputs are not available, representing the Funds’ own assumptions about the assumptions a market
participant would use in valuing the asset or liability, and would be based on the best information available. |
|
12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
Common
Stocks |
|
|
$192,600,605 |
|
|
$ — |
|
|
$ — |
|
|
$192,600,605
|
Total
Investments in Securities* |
|
|
$192,600,605 |
|
|
$ — |
|
|
$ — |
|
|
$192,600,605 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
Common
Stocks |
|
|
$35,800,290 |
|
|
$ — |
|
|
$ — |
|
|
$35,800,290
|
Total
Investments in Securities* |
|
|
$35,800,290 |
|
|
$ — |
|
|
$ — |
|
|
$35,800,290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* |
Refer to the Schedule of Investments for further
information on the classification of investments. |
|
|
|
|
|
|
|
|
|
|
Equity Fund |
|
|
ESG Fund
|
Expiration |
|
|
Amount |
|
|
Amount |
February 2025
– July 2025 |
|
|
$— |
|
|
$68,806
|
August 2025
– July 2026 |
|
|
18,086 |
|
|
122,788
|
August 2026
– July 2027 |
|
|
105,779 |
|
|
149,547
|
August 2027
– July 2028 |
|
|
103,629 |
|
|
75,009 |
|
|
|
|
|
|
|
|
13 |
|
|
|
|
|
|
|
|
|
|
|
Period Ended
January 31,
2025 |
|
|
Year Ended
July 31,
2024 |
Shares
sold |
|
|
794,799 |
|
|
4,697,052
|
Shares
issued to holders in reinvestment of distributions |
|
|
2,117,047 |
|
|
3,494,249
|
Shares
redeemed |
|
|
(15,917,865) |
|
|
(32,863,732)
|
Net
decrease in shares outstanding |
|
|
(13,006,019) |
|
|
(24,672,431) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period Ended
January 31,
2025 |
|
|
Year Ended
July 31,
2024 |
Shares
sold |
|
|
74,050 |
|
|
336,207
|
Shares
issued to holders in reinvestment of distributions |
|
|
62,499 |
|
|
89,596
|
Shares
redeemed |
|
|
(906,774) |
|
|
(1,213,374)
|
Net
decrease in shares outstanding |
|
|
(770,225) |
|
|
(787,571) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
|
|
|
Equity Fund |
|
|
ESG Fund
| ||||||
|
|
|
Purchases |
|
|
Sales |
|
|
Purchases |
|
|
Sales |
U.S.
Government Securities |
|
|
$— |
|
|
$— |
|
|
$— |
|
|
$—
|
Other
Securities |
|
|
$37,498,898 |
|
|
$244,881,053 |
|
|
$5,794,565 |
|
|
$15,462,280 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate
Gross
Appreciation |
|
|
Aggregate
Gross
Depreciation |
|
|
Net
Unrealized
Appreciation |
|
|
Federal
Income
Tax Cost
|
Equity
Fund |
|
|
$73,660,046 |
|
|
$(29,700,684) |
|
|
$43,959,362 |
|
|
$359,115,172
|
ESG
Fund |
|
|
5,615,771 |
|
|
(3,069,773) |
|
|
2,545,998 |
|
|
43,124,063 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Undistributed
Ordinary
Income |
|
|
Undistributed
Long-Term
Capital Gains |
|
|
Other
Accumulated
Losses |
|
|
Net
Unrealized
Appreciation |
|
|
Total
Distributable
Earnings
|
Equity
Fund |
|
|
$4,072,470 |
|
|
$20,755,184 |
|
|
$— |
|
|
$43,959,362 |
|
|
$68,787,016
|
ESG
Fund |
|
|
715,639 |
|
|
— |
|
|
(1,655,645) |
|
|
2,545,998 |
|
|
1,605,992 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary
Income* |
|
|
Long Term
Capital Gains |
|
|
Total |
Equity
Fund |
|
|
$6,160,938 |
|
|
$28,342,092 |
|
|
$34,503,030
|
ESG
Fund |
|
|
715,639 |
|
|
— |
|
|
715,639 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary
Income* |
|
|
Long Term
Capital Gains |
|
|
Total |
Equity
Fund |
|
|
$12,266,026 |
|
|
$55,213,833 |
|
|
$67,479,859
|
ESG
Fund |
|
|
740,444 |
|
|
286,656 |
|
|
1,027,100 |
|
|
|
|
|
|
|
|
|
|
* |
For federal income tax purposes, distributions
of short-term capital gains are treated as ordinary income distributions. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fund |
|
|
LOC Agent |
|
|
Average
Borrowings |
|
|
Amount
Outstanding
as of
January 31,
2025 |
|
|
Interest
Expense |
|
|
Maximum
Borrowing |
|
|
Date of
Maximum
Borrowing
|
Equity
Fund |
|
|
U.S.
Bank N.A. |
|
|
$205,223 |
|
|
$ — |
|
|
$8,008 |
|
|
$22,370,000 |
|
|
December 23,
2024 |
ESG
Fund |
|
|
U.S.
Bank N.A. |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15 |
|
|
16 |
|
(b) | Financial Highlights are included within the financial statements filed under Item 7 of this Form.” |
Item 8. Changes in and Disagreements with Accountants for Open-End Investment Companies.
There were no changes in or disagreements with accountants during the period covered by this report.
Item 9. Proxy Disclosure for Open-End Investment Companies.
There were no matters submitted to a vote of shareholders during the period covered by this report.
Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Investment Companies.
See Item 7(a).
Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.
Not applicable
Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.
Not applicable to open-end investment companies.
Item 13. Portfolio Managers of Closed-End Management Investment Companies.
Not applicable to open-end investment companies.
Item 14. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.
Not applicable to open-end investment companies.
Item 15. Submission of Matters to a Vote of Security Holders.
There have been no material changes to the procedures by which shareholders may recommend nominees to the registrant’s board of trustees.
Item 16. Controls and Procedures.
(a) | The Registrant’s Principal Executive Officer and Principal Financial Officer have reviewed the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “Act”)) as of a date within 90 days of the filing of this report, as required by Rule 30a-3(b) under the Act and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934. Based on their review, such officers have concluded that the disclosure controls and procedures are effective in ensuring that information required to be disclosed in this report is appropriately recorded, processed, summarized and reported and made known to them by others within the Registrant and by the Registrant’s service provider. |
(b) | There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Registrant's internal control over financial reporting. |
Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies
Not applicable to open-end investment companies.
Item 18. Recovery of Erroneously Awarded Compensation.
Not applicable
Item 19. Exhibits.
(a) | (1) Any code of ethics or amendment thereto, that is the subject of the disclosure required by Item 2, to the extent that the registrant intends to satisfy Item 2 requirements through filing an exhibit. Not applicable for semi-annual reports. |
(2) Not applicable
(4) Not applicable to open-end investment companies
(5) Not applicable to open-end investment companies
(b) | Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Furnished herewith. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
(Registrant) | Managed Portfolio Series |
By (Signature and Title)* | /s/ Brian R. Wiedmeyer | ||
Brian R. Wiedmeyer, Principal Executive Officer |
Date | April 9, 2025 |
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By (Signature and Title)* | /s/ Brian R. Wiedmeyer | ||
Brian R. Wiedmeyer, Principal Executive Officer |
Date | April 9, 2025 |
By (Signature and Title)* | /s/ Benjamin J. Eirich | ||
Benjamin J. Eirich, Principal Financial Officer |
Date | April 9, 2025 |
* Print the name and title of each signing officer under his or her signature.